| Record Information |
|---|
| Version | 2.0 |
|---|
| Created at | 2022-05-11 16:41:07 UTC |
|---|
| Updated at | 2022-05-11 16:41:07 UTC |
|---|
| NP-MRD ID | NP0087136 |
|---|
| Secondary Accession Numbers | None |
|---|
| Natural Product Identification |
|---|
| Common Name | 6-Hydroxymelatonin |
|---|
| Description | 6-Hydroxymelatonin, also known as lopac-H-0627, belongs to the class of organic compounds known as hydroxyindoles. These are organic compounds containing an indole moiety that carries a hydroxyl group. 6-Hydroxymelatonin is an extremely weak basic (essentially neutral) compound (based on its pKa). 6-Hydroxymelatonin exists in all living organisms, ranging from bacteria to humans. 6-Hydroxymelatonin can be biosynthesized from melatonin; which is catalyzed by the enzyme cytochrome P450 1A1. In humans, 6-hydroxymelatonin is involved in tryptophan metabolism. Outside of the human body, 6-Hydroxymelatonin has been detected, but not quantified in, several different foods, such as beans, new zealand spinachs, ginsengs, mountain yams, and scarlet beans. This could make 6-hydroxymelatonin a potential biomarker for the consumption of these foods. Similar to melatonin, 6-OHM is a full agonist of the MT1 and MT2 receptors. It is also an antioxidant and neuroprotective, and is even more potent in this regard relative to melatonin. 6-Hydroxymelatonin is found in Mus musculus. 6-Hydroxymelatonin was first documented in 1987 (PMID: 3035087). 6-Hydroxymelatonin (6-OHM) is a naturally occurring, endogenous, major active metabolite of melatonin (PMID: 15356035) (PMID: 16300638) (PMID: 22430231) (PMID: 3608151) (PMID: 7562371) (PMID: 3436070). |
|---|
| Structure | COC1=C(O)C=C2NC=C(CCNC(C)=O)C2=C1 InChI=1S/C13H16N2O3/c1-8(16)14-4-3-9-7-15-11-6-12(17)13(18-2)5-10(9)11/h5-7,15,17H,3-4H2,1-2H3,(H,14,16) |
|---|
| Synonyms | | Value | Source |
|---|
| Lopac-H-0627 | ChEBI | | 6-Oxymelatonin | HMDB | | 6-Hydroxy-N-acetyl-5-methoxytryptamine | HMDB | | 6-Hydroxy-N-acetyl-5-methoxytryptamine | HMDB |
|
|---|
| Chemical Formula | C13H16N2O3 |
|---|
| Average Mass | 248.2777 Da |
|---|
| Monoisotopic Mass | 248.11609 Da |
|---|
| IUPAC Name | N-[2-(6-hydroxy-5-methoxy-1H-indol-3-yl)ethyl]acetamide |
|---|
| Traditional Name | N-[2-(6-hydroxy-5-methoxy-1H-indol-3-yl)ethyl]acetamide |
|---|
| CAS Registry Number | Not Available |
|---|
| SMILES | COC1=C(O)C=C2NC=C(CCNC(C)=O)C2=C1 |
|---|
| InChI Identifier | InChI=1S/C13H16N2O3/c1-8(16)14-4-3-9-7-15-11-6-12(17)13(18-2)5-10(9)11/h5-7,15,17H,3-4H2,1-2H3,(H,14,16) |
|---|
| InChI Key | OMYMRCXOJJZYKE-UHFFFAOYSA-N |
|---|
| Experimental Spectra |
|---|
|
| Not Available | | Predicted Spectra |
|---|
|
| | Spectrum Type | Description | Depositor ID | Depositor Organization | Depositor | Deposition Date | View |
|---|
| 1D NMR | 13C NMR Spectrum (1D, 25 MHz, D2O, predicted) | Wishart Lab | Wishart Lab | David Wishart | 2021-06-20 | View Spectrum | | 1D NMR | 1H NMR Spectrum (1D, 100 MHz, D2O, predicted) | Wishart Lab | Wishart Lab | David Wishart | 2021-06-20 | View Spectrum | | 1D NMR | 13C NMR Spectrum (1D, 252 MHz, D2O, predicted) | Wishart Lab | Wishart Lab | David Wishart | 2021-06-20 | View Spectrum | | 1D NMR | 1H NMR Spectrum (1D, 1000 MHz, D2O, predicted) | Wishart Lab | Wishart Lab | David Wishart | 2021-06-20 | View Spectrum | | 1D NMR | 13C NMR Spectrum (1D, 50 MHz, D2O, predicted) | Wishart Lab | Wishart Lab | David Wishart | 2021-06-20 | View Spectrum | | 1D NMR | 1H NMR Spectrum (1D, 200 MHz, D2O, predicted) | Wishart Lab | Wishart Lab | David Wishart | 2021-06-20 | View Spectrum | | 1D NMR | 13C NMR Spectrum (1D, 75 MHz, D2O, predicted) | Wishart Lab | Wishart Lab | David Wishart | 2021-06-20 | View Spectrum | | 1D NMR | 1H NMR Spectrum (1D, 300 MHz, D2O, predicted) | Wishart Lab | Wishart Lab | David Wishart | 2021-06-20 | View Spectrum | | 1D NMR | 13C NMR Spectrum (1D, 101 MHz, D2O, predicted) | Wishart Lab | Wishart Lab | David Wishart | 2021-06-20 | View Spectrum | | 1D NMR | 1H NMR Spectrum (1D, 400 MHz, D2O, predicted) | Wishart Lab | Wishart Lab | David Wishart | 2021-06-20 | View Spectrum | | 1D NMR | 13C NMR Spectrum (1D, 126 MHz, D2O, predicted) | Wishart Lab | Wishart Lab | David Wishart | 2021-06-20 | View Spectrum | | 1D NMR | 1H NMR Spectrum (1D, 500 MHz, D2O, predicted) | Wishart Lab | Wishart Lab | David Wishart | 2021-06-20 | View Spectrum | | 1D NMR | 13C NMR Spectrum (1D, 151 MHz, D2O, predicted) | Wishart Lab | Wishart Lab | David Wishart | 2021-06-20 | View Spectrum | | 1D NMR | 1H NMR Spectrum (1D, 600 MHz, D2O, predicted) | Wishart Lab | Wishart Lab | David Wishart | 2021-06-20 | View Spectrum | | 1D NMR | 13C NMR Spectrum (1D, 176 MHz, D2O, predicted) | Wishart Lab | Wishart Lab | David Wishart | 2021-06-20 | View Spectrum | | 1D NMR | 1H NMR Spectrum (1D, 700 MHz, D2O, predicted) | Wishart Lab | Wishart Lab | David Wishart | 2021-06-20 | View Spectrum | | 1D NMR | 13C NMR Spectrum (1D, 201 MHz, D2O, predicted) | Wishart Lab | Wishart Lab | David Wishart | 2021-06-20 | View Spectrum | | 1D NMR | 1H NMR Spectrum (1D, 800 MHz, D2O, predicted) | Wishart Lab | Wishart Lab | David Wishart | 2021-06-20 | View Spectrum | | 1D NMR | 13C NMR Spectrum (1D, 226 MHz, D2O, predicted) | Wishart Lab | Wishart Lab | David Wishart | 2021-06-20 | View Spectrum | | 1D NMR | 1H NMR Spectrum (1D, 900 MHz, D2O, predicted) | Wishart Lab | Wishart Lab | David Wishart | 2021-06-20 | View Spectrum |
| | Chemical Shift Submissions |
|---|
|
| Not Available | | Species |
|---|
| Species of Origin | |
|---|
| Chemical Taxonomy |
|---|
| Description | Belongs to the class of organic compounds known as hydroxyindoles. These are organic compounds containing an indole moiety that carries a hydroxyl group. |
|---|
| Kingdom | Organic compounds |
|---|
| Super Class | Organoheterocyclic compounds |
|---|
| Class | Indoles and derivatives |
|---|
| Sub Class | Hydroxyindoles |
|---|
| Direct Parent | Hydroxyindoles |
|---|
| Alternative Parents | |
|---|
| Substituents | - Hydroxyindole
- 3-alkylindole
- Indole
- Anisole
- Alkyl aryl ether
- 1-hydroxy-2-unsubstituted benzenoid
- Substituted pyrrole
- Benzenoid
- Pyrrole
- Heteroaromatic compound
- Azacycle
- Ether
- Carboximidic acid derivative
- Carboximidic acid
- Propargyl-type 1,3-dipolar organic compound
- Organic 1,3-dipolar compound
- Organic oxygen compound
- Hydrocarbon derivative
- Organic nitrogen compound
- Organooxygen compound
- Organonitrogen compound
- Organopnictogen compound
- Aromatic heteropolycyclic compound
|
|---|
| Molecular Framework | Aromatic heteropolycyclic compounds |
|---|
| External Descriptors | |
|---|
| Physical Properties |
|---|
| State | Not Available |
|---|
| Experimental Properties | | Property | Value | Reference |
|---|
| Melting Point | Not Available | Not Available | | Boiling Point | Not Available | Not Available | | Water Solubility | Not Available | Not Available | | LogP | Not Available | Not Available |
|
|---|
| Predicted Properties | |
|---|
| General References | - Higa S, Suzuki T, Sakoda S, Kishimoto S, Takaba Y, Nakajima A, Markey SP: Disturbed function of the pineal gland in familial amyloid polyneuropathy. J Neural Transm. 1987;69(1-2):97-103. [PubMed:3035087 ]
- Frisch H, Waldhauser F, Waldhor T, Mullner-Eidenbock A, Neupane P, Schweitzer K: Increase in 6-hydroxymelatonin excretion in humans during ascent to high altitudes. J Clin Endocrinol Metab. 2004 Sep;89(9):4388-90. doi: 10.1210/jc.2003-032214. [PubMed:15356035 ]
- Maharaj DS, Maharaj H, Daya S, Glass BD: Melatonin and 6-hydroxymelatonin protect against iron-induced neurotoxicity. J Neurochem. 2006 Jan;96(1):78-81. doi: 10.1111/j.1471-4159.2005.03532.x. Epub 2005 Nov 21. [PubMed:16300638 ]
- Ozkan E, Yaman H, Cakir E, Deniz O, Oztosun M, Gumus S, Akgul EO, Agilli M, Cayci T, Kurt YG, Aydin I, Arslan Y, Ilhan N, Ilhan N, Erbil MK: Plasma melatonin and urinary 6-hydroxymelatonin levels in patients with pulmonary tuberculosis. Inflammation. 2012 Aug;35(4):1429-34. doi: 10.1007/s10753-012-9456-3. [PubMed:22430231 ]
- Bojkowski CJ, Arendt J, Shih MC, Markey SP: Melatonin secretion in humans assessed by measuring its metabolite, 6-sulfatoxymelatonin. Clin Chem. 1987 Aug;33(8):1343-8. [PubMed:3608151 ]
- Whitson PA, Putcha L, Chen YM, Baker E: Melatonin and cortisol assessment of circadian shifts in astronauts before flight. J Pineal Res. 1995 Apr;18(3):141-7. doi: 10.1111/j.1600-079x.1995.tb00152.x. [PubMed:7562371 ]
- Nowak R, McMillen IC, Redman J, Short RV: The correlation between serum and salivary melatonin concentrations and urinary 6-hydroxymelatonin sulphate excretion rates: two non-invasive techniques for monitoring human circadian rhythmicity. Clin Endocrinol (Oxf). 1987 Oct;27(4):445-52. doi: 10.1111/j.1365-2265.1987.tb01172.x. [PubMed:3436070 ]
- Bruce J, Tamarkin L, Riedel C, Markey S, Oldfield E: Sequential cerebrospinal fluid and plasma sampling in humans: 24-hour melatonin measurements in normal subjects and after peripheral sympathectomy. J Clin Endocrinol Metab. 1991 Apr;72(4):819-23. doi: 10.1210/jcem-72-4-819. [PubMed:2005207 ]
- Francis PL, Leone AM, Young IM, Stovell P, Silman RE: Gas chromatographic-mass spectrometric assay for 6-hydroxymelatonin sulfate and 6-hydroxymelatonin glucuronide in urine. Clin Chem. 1987 Apr;33(4):453-7. [PubMed:3829375 ]
- Hartter S, Ursing C, Morita S, Tybring G, von Bahr C, Christensen M, Rojdmark S, Bertilsson L: Orally given melatonin may serve as a probe drug for cytochrome P450 1A2 activity in vivo: a pilot study. Clin Pharmacol Ther. 2001 Jul;70(1):10-6. doi: 10.1067/mcp.2001.116512. [PubMed:11452239 ]
|
|---|